The Prognostic Power of Dual-Positive Circulating Tumor Cells in Metastatic Breast Cancer
A recent study in *Science Translational Medicine* investigates the metastatic potential and prognostic value of dual-positive circulating tumor cells (CTCs) in patients with advanced breast cancer. The research focuses on a specific subset of CTCs that co-express both epithelial and mesenchymal markers, a phenotype associated with enhanced metastatic capability. By analyzing these cells, the study provides critical insights into tumor biology, offering a potential liquid biopsy biomarker for assessing disease progression, metastasis, and patient outcomes in real-time, moving beyond traditional tissue-based diagnostics.
Study Significance: For pathologists and molecular diagnosticians, this work underscores the evolving role of liquid biopsies in cancer management. The identification of dual-positive CTCs as a prognostic tool directly impacts tumor grading and staging paradigms, offering a dynamic, minimally invasive method to monitor treatment response and disease evolution. This advancement in biomarker discovery could refine diagnostic accuracy and guide more personalized therapeutic strategies for patients with metastatic disease.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
